Withuspharmaceutical Co.Ltd (330350) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Withuspharmaceutical Co.Ltd KRW 7,222, price KRW 7,160, upside +0.9%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Withuspharmaceutical Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 5,528 KRW – 15,251 KRW · fair‑value band 5,335 KRW – 9,885 KRW · the 7,160 KRW price screens below the 7,222 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Withuspharmaceutical Co.Ltd in your weekly email
Every Wednesday you see whether Withuspharmaceutical Co.Ltd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea.
Show more
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products. The company was previously known as Withers Medipharm Co. , Ltd. and changed its name to WITHUS PHARMACEUTICAL Co.,LTD. in October 2007. WITHUS PHARMACEUTICAL Co.,LTD. was founded in 2004 and is headquartered in Seoul, South Korea.
Stock analysis
Withuspharmaceutical Co.Ltd (330350) currently trades at 7,160 KRW, while our model-based Fair Value estimate is 7,222 KRW, implying the stock looks roughly 0.9% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 9,157 KRW per share, and 13 of the 26 models we run sit above the 7,160 KRW price.
Bear case: the Dividend Discount group reads lowest at 1,106 KRW, and 13 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: 5,335 KRW (bear) to 9,885 KRW (bull), the price of 7,160 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Withuspharmaceutical Co.Ltd reported revenue of 106B KRW in FY2025 versus 57.4B KRW in FY2021, a compound +16.7%/yr. Reported net income was 5.0B KRW in FY2025, compounding +3.9%/yr from FY2021.
Key figures
Market cap 94.5B KRW (≈ $69.5M) · P/S ratio 0.76 · Dividend yield 1.6% · Net margin 4.7% · Return on equity 7.4% · Return on assets (EBIT) 4.5% · Operating margin 0.9% · Revenue (TTM) 109B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 40% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at 1%, 330350 screens cheaper than that median.
Fair Value models
Bear 5,335 KRWFair Value 7,222 KRWBull 9,885 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+4.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+3.1%
Dividend (yield on the price)1.6%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 5%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +18.1% a year for the price.
Compare Withuspharmaceutical Co.Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks
Beats the industry median on 6/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score61 · Above median
Fair Value upside+1% · Above median
Profitability
Return on equity (TTM)7% · Above median
Return on assets2% · Below median
Net margin (TTM)7% · Below median
Operating margin (TTM)1% · Below median
Growth and dividend
Revenue growth10% · Above median
Dividend yield (TTM)1.6% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Withuspharmaceutical Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/330350
Frequently asked questions
Is Withuspharmaceutical Co.Ltd (330350) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 7,222 KRW versus a price of 7,160 KRW, about +1% upside (fairly valued).
What is the fair value of 330350?
Our model-based fair value for Withuspharmaceutical Co.Ltd is 7,222 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 7,160 KRW.
What is the quality score of 330350?
Withuspharmaceutical Co.Ltd has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Withuspharmaceutical Co.Ltd (330350)?
Our model-based price target is the fair value of 7,222 KRW (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 5,335 KRW, optimistic scenario 9,885 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Withuspharmaceutical Co.Ltd stock forecast for 2026?
Our models put fair value at 7,222 KRW, about +1% upside versus a price of 7,160 KRW (fairly valued). Cautious scenario 5,335 KRW, optimistic scenario 9,885 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Withuspharmaceutical Co.Ltd (330350)?
Withuspharmaceutical Co.Ltd reported trailing-twelve-month revenue of about 109B KRW (latest available figure, as of Sep 24, 2026).
Does Withuspharmaceutical Co.Ltd pay a dividend?
Withuspharmaceutical Co.Ltd currently shows a dividend yield of about 1.60% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Withuspharmaceutical Co.Ltd (330350)?
For today's price to be fair in a discounted-cash-flow model, Withuspharmaceutical Co.Ltd would have to grow free cash flow by +20.5 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +32.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 330350 use?
Our models discount Withuspharmaceutical Co.Ltd at 12.1 %: a base by market capitalisation (micro), damped by beta 0.68, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Withuspharmaceutical Co.Ltd that is +20.5 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Withuspharmaceutical Co.Ltd (330350) delivered so far?
Over the past 5 years revenue at Withuspharmaceutical Co.Ltd grew +32.4 % a year. The price currently implies +20.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Withuspharmaceutical Co.Ltd (330350) growing?
The median revenue growth in the sector is +1.8 % a year. That is the yardstick for the growth priced into Withuspharmaceutical Co.Ltd (+20.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Withuspharmaceutical Co.Ltd (330350)?
The free-cash-flow yield on the price is 3.88 %: that much free cash flow Withuspharmaceutical Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Withuspharmaceutical Co.Ltd (330350)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Withuspharmaceutical Co.Ltd it is 7,222 KRW per share (as of Sep 24, 2026), against a price of 7,160 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Withuspharmaceutical Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 330350 trades below its calculated fair value: price 7,160 KRW, fair value 7,222 KRW, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 330350?
No. The price is what the market pays today (7,160 KRW); the fair value is what the company's own numbers justify (7,222 KRW). For Withuspharmaceutical Co.Ltd the two are 61.55 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Withuspharmaceutical Co.Ltd worth?
The market values Withuspharmaceutical Co.Ltd at about 94.5B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 7,160 KRW; our models calculate a fair value of 7,222 KRW per share.
What do the bullish and bearish scenarios say about 330350?
Our models span a range for Withuspharmaceutical Co.Ltd: cautious scenario 5,335 KRW, base 7,222 KRW, optimistic 9,885 KRW per share (as of Sep 24, 2026, price 7,160 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Withuspharmaceutical Co.Ltd (330350)?
Balance-sheet figures for Withuspharmaceutical Co.Ltd (as of Sep 24, 2026): return on equity 7.4%, debt of 0.02 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 330350 from its 52-week high?
Withuspharmaceutical Co.Ltd trades at 7,160 KRW, about 40% below its 52-week high of 11,940 KRW and 19% above the low of 6,010 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 7,222 KRW is for.
Which stocks are comparable to Withuspharmaceutical Co.Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Withuspharmaceutical Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 7,160 KRW, calculated fair value 7,222 KRW (+1%), Quality Score 61/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 330350 calculated?
We run Withuspharmaceutical Co.Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 7,222 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Withuspharmaceutical Co.Ltd currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Withuspharmaceutical Co.Ltd (330350)?
The closing price on Sep 23, 2026 was 7,160 KRW. Our model-based fair value is 7,222 KRW, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Withuspharmaceutical Co.Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (5,335 KRW to 9,885 KRW) leaves room in how you read the outcome.
Key figures of Withuspharmaceutical Co.Ltd
How large is the market capitalisation of Withuspharmaceutical Co.Ltd (330350)?
The market capitalisation of Withuspharmaceutical Co.Ltd is 94.5B KRW (≈ $69.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Withuspharmaceutical Co.Ltd (330350)?
The price-to-sales ratio of Withuspharmaceutical Co.Ltd is 0.76 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Withuspharmaceutical Co.Ltd (330350)?
The dividend yield of Withuspharmaceutical Co.Ltd is 1.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Withuspharmaceutical Co.Ltd (330350)?
The net margin of Withuspharmaceutical Co.Ltd is 4.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Withuspharmaceutical Co.Ltd (330350)?
The return on equity (ROE) of Withuspharmaceutical Co.Ltd is 7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Withuspharmaceutical Co.Ltd (330350)?
On an EBIT basis the return on assets of Withuspharmaceutical Co.Ltd is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Withuspharmaceutical Co.Ltd (330350)?
The operating margin of Withuspharmaceutical Co.Ltd is 0.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Withuspharmaceutical Co.Ltd (330350)?
Revenue at Withuspharmaceutical Co.Ltd is growing +9.5% versus a year earlier (3y avg +18.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Withuspharmaceutical Co.Ltd (330350)?
Earnings per share at Withuspharmaceutical Co.Ltd are growing +141% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Withuspharmaceutical Co.Ltd (330350) carry?
The net debt of Withuspharmaceutical Co.Ltd is 944M KRW (fiscal year 2025, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Withuspharmaceutical Co.Ltd in the live analysis
One click puts Withuspharmaceutical Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
